Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
International Journal of Pharmaceutics|February 22, 2011
New insights into respirable protein powder preparation using a nano spray dryerK Bürki, I Jeon, C Arpagaus, et al.
Laboratory Animals|November 10, 1998
Adverse effects of tribromoethanol as used in the production of transgenic miceW Zeller, G Meier, K Bürki, et al.
The American Journal of Surgical Pathology|August 1, 1992
Recurrent cutaneous anaplastic large cell (CD30+) lymphoma associated with Epstein-Barr virus. A case report with 9-year follow-upB Borisch, J Böni, K Bürki, et al.
Transgenic Research|November 1, 1996
Efficient targeting of the IL-4 gene in a BALB/c embryonic stem cell lineN Noben-Trauth, G Köhler, K Bürki, et al.
Virchows Archiv. A, Pathological Anatomy and Histopathology|January 1, 1992
Enteropathy-associated T-cell lymphoma in a renal transplant patient with evidence of Epstein-Barr virus involvementB Borisch, I Hennig, F Horber, et al.
European Journal of Immunology|May 1, 1992
High-level expression of a human immunoglobulin gamma 1 transgene depends on switch region sequencesH Gram, G Zenke, S Geisse, et al.
European Journal of Immunology|February 1, 1996
Identification and characterization of a human CD4 silencerA Donda, M Schulz, K Bürki, et al.
Nature|November 30, 1989
Tolerance induction in double specific T-cell receptor transgenic mice varies with antigenH Pircher, K Bürki, R Lang, et al.
Onkologie|April 1, 1989
ABLETOP, a well-tolerated, effective regimen for relapsing Hodgkin's disease. Swiss Group for Clinical Cancer Research (SAKK)R Obrist, H P Honegger, M Aapro, et al.
European Journal of Immunology|December 1, 1994
CD8+ T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicityD Kägi, B Ledermann, K Bürki, et al.
Pageof 7